SEATTLE, June 10 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (“CTI”) announced today that a summary of the pixantrone Phase III clinical data that were presented at American Society of Clinical Oncology (ASCO) 2009 Annual Meeting on June 1, 2009 is now available at Clinical Care Options website http://www.clinicaloptions.com. Clinical Care Options is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs. The ASCO summaries are “quick read” reviews of key oral sessions and poster presentations, which are handpicked by leading experts in oncology and hematology for the Clinical Care Options website.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.
CONTACT: Media, Dan Eramian , +1-206-272-4343, cell, +1-206-854-1200,
deramian@ctiseattle.com, or Investors, Ed Bell, +1-206-282-7100, or Lindsey
Jesch Logan, +1-206-272-4347, fax, +1-206-272-4434, invest@ctiseattle.com,
all of Cell Therapeutics, Inc.
Web site: http://www.celltherapeutics.com/
http://www.clinicaloptions.com/
